G. Michael Allan

Sep 13, 2024 | cfp.ca | Emélie Braschi |Jennifer Young |G. Michael Allan

Clinical questionWhat are the risks and benefits of using topical corticosteroids for atopic dermatitis in children and adults? Bottom lineWhile evidence is limited, topical steroids are effective against atopic dermatitis and efficacy likely increases with potency. Use once daily seems as effective as twice daily. Treatment 2 days per week of areas with frequent recurrent flares will help about 60% avoid a flare versus about 30% using a placebo over 16 weeks.

Sep 13, 2024 | cfp.ca | Emélie Braschi |Jennifer Young |G. Michael Allan

Question cliniqueQuels sont les risques et les bienfaits d’utiliser des corticostéroïdes topiques pour la dermatite atopique chez les enfants et les adultes? RésultatsBien que les données probantes soient limitées, les corticostéroïdes topiques sont efficaces contre la dermatite atopique, et leur efficacité augmente probablement en fonction de leur puissance. L’application 1 fois par jour semble aussi efficace que l’application 2 fois par jour.

Jun 17, 2024 | cfp.ca | Michael R Kolber |Adrienne Lindblad |Scott W. Klarenbach |G. Michael Allan

We thank Dr Aubrey-Bassler for his comment1 pertaining to the PEER simplified lipid guideline 2023 update.2 Both the 2023 and 2015 PEER simplified lipid guidelines do not recommend repeat lipid testing for primary or secondary prevention patients, or treating to a target low-density lipoprotein level after initiation of statins.2,3 In our guideline we state, “In secondary prevention, if additional cardiovascular risk reduction is desired beyond maximized statin therapy, we recommend a...

May 14, 2024 | cfp.ca | Jennifer Young |G. Michael Allan |Betsy Thomas

Clinical questionDo cranberry products prevent recurrent urinary tract infections (UTIs)? Bottom lineEvidence is of low quality because of potential publication bias, small studies, and unblinding. If biases are disregarded, cranberry products might reduce the proportion of women with recurrent UTIs to 18% vs 24% with placebo over 1 year or less. Results are inconsistent between populations (eg, children with recurrent UTIs may benefit but not institutionalized elderly patients or pregnant women).

Apr 16, 2024 | cfp.ca | Danielle Perry |G. Michael Allan

Clinical questionHow effective and safe is respiratory syncytial virus (RSV) vaccination in older adults? Bottom lineFor roughly every 380 medically stable patients (≥60 years), RSV vaccination prevents 1 RSV-associated lower respiratory tract disease (LRTD) per season (vs placebo). Fatigue occurs in 34% of patients (vs 16% placebo). Guidance suggests administering based on shared decision making, mainly in those at higher risk. EvidenceResults were statistically different unless indicated.